REGULATORY
Industry Representatives Express Concern over Large Reductions in Prices of Long-Listed Drugs at CSIMC
The Central Social Insurance Medical Council’s (CSIMC) Expert Subcommittee on NHI Drug Pricing Affairs (chairperson: Prof. Mariko Nishimura, Meiji Gakuin University) discussed the pricing of long-listed drugs at a meeting on July 18. Representatives of the pharmaceutical industry expressed strong…
To read the full story
REGULATORY
- LDP Pharma Project Team to Compile Roadmap Proposals after Industry Hearings
April 17, 2026
- DPJ Leader to Urge Drug Price Hikes, “Freeze” on Off-Year Revisions
April 17, 2026
- Japan Eases Documentation Requirements for Excipients Listed in Foreign Pharmacopoeias
April 17, 2026
- Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
April 16, 2026
- MHLW to Set Criteria for Exemptions under OTC-Like Drug Charge Scheme
April 16, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





